Clinical Efficacy of Ceftazidime-Avibactam in the Treatment of Infections Caused by Carbapenem–Resistant Gram-Negative Bacteria
- 21 October 2021
- journal article
- Published by Publishing House OKI in Antibiotics and Chemotherapy
- Vol. 66 (7-8), 67-82
- https://doi.org/10.37489/0235-2990-2021-66-7-8-67-82
Abstract
The wide spread of carbapenemases among gram-negative bacteria of the Enterobacterales order in hospitals around the world, including Russia, creates great difficulties in the effective use of antibiotics for these infections in the ICU. Ceftazidime-avibactam is the first antibiotic developed and studied for the treatment of infections caused by carbapenem-resistant enterobacteria. Ceftazidime-avibactam shows high activity against producers of class A and D serine carbapenemases (KPC and OXA-48). In combination with aztreonam it is effective in infections caused by producers of class B metallo-beta-lactamases (NDM and VIM). The review analyzes the results of 19 non-comparative and 10 comparative studies of ceftazidime-avibactam in infections caused by carbapenem-resistant Enterobacterales, as well as case reports. According to the data of non- comparative studies, the clinical efficacy of ceftazidime-avibactam ranged from 45.0 to 87.2%, on average 71.7±11.3%, and the eradication rate of KPC or OXA-48 carbapenemase producers ranged from 40.0 to 100%, on average 65.5±18.6%. The effectiveness of ceftazidime-avibactam in comparative studies was 67.9±17.3%, which was significantly higher compared to other antibiotics (44.3±14.4%,P=0.012). Treatment with ceftazidime-avibactam was accompanied by a significantly lower 30-day mortality in contrast to other antibiotics – 23.8±13.5% and 41.0±13.6%, respectively,P=0.001. The development of resistance in Enterobacterales species to ceftazidime-avibactam during therapy is rarely observed, on average 5.4±4.4%, which characterizes a rather low potential of the antibiotic in resistance selection. Early administration of ceftazidime-avibactam is accompanied by better treatment results as opposed to delayed therapy. Treatment of infections caused by carbapenem-resistant enterobacteria with ceftazidime-avibactam is associated with a significantly higher recovery rate and a lower mortality compared to other regimens of antibacterial therapy.Keywords
This publication has 75 references indexed in Scilit:
- Antibiotic Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae: Systematic Evaluation of the Available EvidenceAntimicrobial Agents and Chemotherapy, 2014
- Emergence of Klebsiella pneumoniae producing NDM-1 carbapenemase in Saint Petersburg, RussiaJournal of Antimicrobial Chemotherapy, 2013
- A brief multi-disciplinary review on antimicrobial resistance in medicine and its linkage to the global environmental microbiotaFrontiers in Microbiology, 2013
- Outcome of carbapenem resistant Klebsiella pneumoniae bloodstream infectionsClinical Microbiology & Infection, 2012
- Tackling antibiotic resistanceNature Reviews Microbiology, 2011
- Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence studyThe Lancet Infectious Diseases, 2011
- Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infectionsDiagnostic Microbiology and Infectious Disease, 2011
- Hospital and Societal Costs of Antimicrobial‐Resistant Infections in a Chicago Teaching Hospital: Implications for Antibiotic StewardshipClinical Infectious Diseases, 2009
- Outcomes of Carbapenem-Resistant Klebsiella pneumoniae Infection and the Impact of Antimicrobial and Adjunctive TherapiesInfection Control & Hospital Epidemiology, 2008
- Emergence of Oxacillinase-Mediated Resistance to Imipenem inKlebsiella pneumoniaeAntimicrobial Agents and Chemotherapy, 2004